期刊文献+

改良荧光原位杂交技术检测乳腺癌HER2基因 被引量:3

Improved Fluorescent in situ Hybridization in Detection of Breast Cancer HER2 Gene
下载PDF
导出
摘要 目的探讨改良荧光原位杂交(fluorescent in situ hybridization,FISH)技术在检测乳腺癌HER2基因中的应用。方法对52例经免疫组化(immunohistochemistry,IHC)法检测HER2的乳腺癌标本行改良FISH法检测HER2基因扩增情况,Kappa检验法对两种检测结果的一致性进行统计分析。结果改良FISH法成功率高,与IHC法检测结果一致性好,两者实际一致率为88.5%(K=0.757,P=0.000)。结论改良FISH技术可作为最终确诊HER2基因状态的方法 。 Objective To investigate the implication of improved fluorescent in situ hybridization (FISH) technique in the detection of HER2 gene in breast cancer tissues.Methods HER2 genes amplification in 52 samples with breast cancer detected by IHC method was tested by improved FISH method.Kappa test was employed to compare the results of the two methods.Results Improved FISH method had high success rate and high coincidence with IHC method.The concordance rate was 88.5% (K=0.757,P=0.000).Conclusion The improved FISH is simple to operate,safe,stable,and highly sensitive in detecting HER2 gene amplification of breast cancer tissue.It can be utilized to diagnose HER2 gene status.
出处 《华南国防医学杂志》 CAS 2010年第3期208-210,共3页 Military Medical Journal of South China
关键词 荧光原位杂交 免疫组化 乳腺癌 HER2基因 Fluorescence in situ hybridization Immunohistochemistry Breast cancer HER2 gene
  • 相关文献

参考文献7

二级参考文献73

  • 1曾瑄,赵大春,周炜洵,武莎斐,梁智勇,刘彤华.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志,2005,34(11):701-705. 被引量:65
  • 2曾瑄,梁智勇,武莎斐,周炜洵,高洁,刘彤华.乳腺癌HER2蛋白表达阳性者的基因状态分析[J].中华病理学杂志,2006,35(10):584-588. 被引量:40
  • 3<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 4吕亚莉,钟梅,赵坡.应用荧光原位杂交法检测乳腺癌石腊样本中HER-2基因的扩增[J].肿瘤防治研究,2007,34(5):345-347. 被引量:19
  • 5吕亚莉 钟梅 赵坡.应用荧光原位杂交技术检测乳腺癌HER-2基因扩增[J].肿瘤防治杂志,2005,12(12):20-21.
  • 6WU F, HU CH,JIANG SA, et al. Herceptin plus adjuvant chemotherapy for the prognosis of patients with human epithelial growth factor receptor 2 positive early-stage breast cancer:a meta-analysis [J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2007,32(4) : 684-689.
  • 7KIMURA M,SANO M,FUJIMORI M,et al. Neoadjuvant paclitaxel for operable breast cancer:multicenter phase Ⅱ trial with clinical outcomes[J]. Anticancer Res, 2008,28 (2B) : 1239-1244.
  • 8CHEN SC,CHANG HK,LIN YC,et al. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin [J ]. Jpn J Clin Oncol,2008,38(2):99-105.
  • 9PETIT T, BOREL C, GHNASSIA JP, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting [J]. Clin Cancer Res,2001,7 (6): 1577-1551.
  • 10GAGO FE, FANELLI MA, CIOCCA DR. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer:clinical outcome following tamoxifen-based adjuvant therapy [J]. Steroid Biochem Mol Biol, 2006,98 ( 1 ) : 36-40.

共引文献283

同被引文献19

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部